Pfizer and Zacharon Pharmaceuticals have entered into a strategic research collaboration to develop drugs for orphan diseases, including lysosomal storage disorders. Zacharon will use its platform for developing small molecule drugs targeting specific carbohydrate polymers or glycans for the potential development of new compounds. Zacharon will receive up-front payments and R&D funding and is eligible to receive development milestones, plus royalties and sales milestones upon commerciali...